Polymyxin B Trimethoprim Composition for Bacterial Keratitis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for bacterial keratitis, particularly those involving fluoroquinolones, face rising resistance issues and limited efficacy due to slow action and poor ocular tissue penetration, necessitating a more effective antimicrobial composition for rapid and broad-spectrum activity against Gram-positive and Gram-negative organisms.
Innovation Solution
A topical anti-bacterial composition combining polymyxin B and trimethoprim with either rifampicin or tobramycin, formulated into a pharmaceutical composition for enhanced antimicrobial efficacy, including a weight ratio range of 1:1000 to 1000:1, to treat ocular, otic, nasal, skin, or wound infections, effectively targeting Staphylococcus aureus, Pseudomonas aeruginosa, and other pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If fourth-generation fluoroquinolones (moxifloxacin or gatifloxacin) are used for broad spectrum activity, then coverage against Gram-positive and Gram-negative organisms is improved, but resistance rates increase significantly
Solution Approach 1:
The patent combines two antibiotics with different mechanisms of action (polymyxin B for Gram-negative and trimethoprim for Gram-positive) into a single formulation, achieving broad spectrum coverage while reducing resistance development through synergistic effects
Solution Approach 2:
The invention creates a composite antibiotic formulation containing polymyxin B and trimethoprim in specific ratios, leveraging the complementary strengths of each component to provide broad spectrum activity with reduced resistance compared to single-agent fluoroquinolones
2Reliability
If trimethoprim-polymyxin B (Polytrim) is used for treatment, then resistance rates remain low, but the treatment is slow acting with limited ocular tissue penetration
Solution Approach 1:
The patent optimizes the concentration ratios of polymyxin B to trimethoprim (specifically 1:1 to 1:10 or 1:20) to enhance the speed of bacterial kill while maintaining the low resistance profile, representing a parameter change from conventional Polytrim formulations
Solution Approach 2:
The formulation is designed to achieve rapid initial bactericidal activity to quickly reduce bacterial load before slower-acting components take full effect, addressing the speed limitation while preserving reliability
3Adaptability or versatility
If Polytrim is used for ocular infections, then broad coverage is achieved, but potency is limited compared to other ophthalmic antimicrobial agents
Solution Approach 1:
The patent merges polymyxin B and trimethoprim in optimized concentrations to achieve synergistic bactericidal activity that exceeds the potency of either agent alone, while maintaining broad Gram-positive and Gram-negative coverage
Solution Approach 2:
The formulation uses higher concentrations of polymyxin B relative to conventional Polytrim (up to 10,000 units/mL compared to typical 5,000-10,000 units/mL) to enhance potency while the synergistic interaction with trimethoprim prevents resistance development
Data Source
Figure 1A
Figure 1B
Figure 2A
AI summary
The present invention features an antibacterial composition comprising 1) a composition A comprising polymyxin B and trimethoprim; and 2) an antibiotic agent selected from the group consisting of rifampicin, rifabutin, rifapentine, rifaximin, pefloxacin mesylate, sparfloxacin, sarafloxacin HCl, tobramycin, lomefloxacin, besifloxacin, danofloxacin mesylate, enrofloxacin, nadifloxacin and clinafloxacin, a topical pharmaceutical thereof, and a method of treating bacterial infections using mixtures of 1 and 2.